ClinicalTrials.Veeva

Menu

Kinetics of Extracellular Vesicles in Hemodialysis

A

Amsterdam UMC, location VUmc

Status

Completed

Conditions

End-stage Kidney Disease

Treatments

Device: Routine hemodialysis

Study type

Observational

Funder types

Other

Identifiers

NCT05957146
NL84115.018.23

Details and patient eligibility

About

The aim of this observational study is to gain insight into the kinetics of extracellular vesicles (EVs), derived from both in- (i.e. bio-incompatibility) and outside (tissue-injury) the extracorporeal circuit (ECC), during standard hemodialysis (HD) in adult prevalent end-stage kidney disease (ESKD) patients treated with HD.

During a single HD session, blood samples for EV-assessment will be taken at several time points and at different sampling sites in the extracorporeal circuit (sampling point 1: before the rollerpump, arterial line; sampling point 2: after the rollerpump and before the dialyzer, sampling point 3: after the dialyzer, efferent line).

Full description

Hemodialysis (HD) is a lifesaving treatment for ESKD patients. Yet, apart from beneficial effects, HD has adverse consequences, which, apart from rapid osmolality and electrolyte shifts, results from the bio-incompatibility (BI) of the extra-corporeal circuit (ECC) and intradialytic hypotension (IDH) as well. While BI arises within the ECC due to the contact between circulating blood cells and the foreign materials of the lines and dialyzer, IDH-induced tissue injury (TI) originates within the body of the patients. Activated cells can be detected by upregulation of cell surface markers and release of degradation products. Substances which are smaller than the pores of dialyzer-membranes may pass this barrier and, thus, become undetectable in blood.

Various cell types shed small particles upon activation an/or injury, so called extracellular vesicles (EVs). These EVs, which are shed by various cell types upon activation and/or injury, contain various proteins and are too large to travers dialyzer membranes. Their assessment requires strict and standardized collection and handling of blood samples. In previous HD research, both pre-analytical circumstances and analytic methods were insufficiently standardized, precluding solid conclusions. Both the contact between circulating blood cells and the ECC, and recurrent IDH, predispose to micro-inflammation and cell activation, which are related to morbidity and mortality. Hence, when analysed properly, the measuring of EVs might be a valuable tool to assess dialysis-induced adverse side-effects, not only in the dialyzer but also in the body, which, when occurring repeatedly, may influence survival.

In a recent study, we found an increase in EVs during treatment with different dialysis modalities. However, EVs were only assessed before and after dialysis. Hence, in the present study, we aim to assess the kinetics of EVs in routine HD.

Enrollment

6 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age >18 years
  • Stable clinical situation: free of infection, no recent admission
  • HD >3 months
  • Haemoglobin level >6,2 mmol/L
  • Residual diuresis <200mL/24h
  • Willing and able to give written informed consent.

Exclusion criteria

  • Active infection, malignancy, auto-immune disease, or treatment with immunosuppressive medication.
  • Allergy to polysulfone dialysers
  • Life expectancy <3 months due to non-renal disease
  • Access recirculation

Trial design

6 participants in 1 patient group

Chronic hemodialysis patients
Description:
Adult patients treated with routine hemodialysis 3x/week during at least 3 months
Treatment:
Device: Routine hemodialysis

Trial contacts and locations

1

Loading...

Central trial contact

Sabrine Chaara, MD; Muriel PC Grooteman, MD PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems